 |
Amgen drug cuts cancer bone problem riskA third pivotal trial of Amgen's denosumab found that it delayed by 21 per cent the risk of fractures and other bone complications in men with advanced prostate cancer compared with current therapy. Amgen filed last month for US Food and D More… |
 |
Amgen osteoporosis drug wins approvalThe US Food and Drug Administration has approved the sale of Amgen's osteoporosis drug Prolia to help prevent fractures in post-menopausal women. The approval comes just days after the medicine received European approval. &n More… |
